Platform

Ischemic Diseases

Hemostemix’s technology platform for developing autologous cell therapies has the potential to treat a broad range of vascular diseases. We are currently developing a treatment for critical limb ischemia, which is considered a gateway indication for broader ischemic diseases that represent a $20B potential global market.

Technology Strengths